United States Patent 8,349,840: What Is Claimed, Where It Sits in the Landscape, and What It Likely Blocks
US Drug Patent 8,349,840 claims a family of heterocyclic small molecules (and salts) defined by a broad structural scaffold with a constrained “ring Q” identity, substitution latitude on ring Q, and a specific variable linker/ring relationship, plus composition claims and CNS-depression treatment method claims that cover specified exemplified compounds.
What does claim scope look like in US 8,349,840?
Core claim architecture
Across independent claims, scope is built from four layers:
- Heterocyclic active ingredient scaffold (formula (1))
- Includes a heterocyclic ring system with variable features Z and Y, plus a specified structural constraint: the carbon-carbon bond between the 3-position and 4-position of the heterocyclic skeleton is either single or double.
- Ring Q identity constraint
- “Ring Q” is defined only within a limited set of ring-atom patterns:
- —NH—CH2—
- —N═CH—
- —CH2—NH—
- —CH═N—
- Ring Q substituent latitude
- Ring Q “may have” substituents from a long list including:
- lower alkyl/alkenyl/alkynyl
- hydroxy, lower alkoxy
- halogenated lower alkyl, halogens
- aryl, aryl lower alkyl/alkoxy, arylcarbonyl
- lower alkenyloxy, lower alkanoyl/alkanoyloxy
- cycloalkyl and cycloalkyl lower alkyl
- carbamoyl (optionally lower alkyl)
- carboxy
- lower alkoxycarbonyl
- amino (optionally lower alkanoyl)
- nitro
- hydroxy lower alkyl, amino lower alkyl (optionally lower alkyl)
- thienyl
- saturated 3- to 8-membered heteromonocycle with 1-2 nitrogen atoms, substituted lower alkyl, and oxo
- Linker A and variable ring condition (important narrowing trigger)
- A represents —O-A1- or a lower alkylene group
- If A is a lower alkylene group, then ring Q must be a bicyclic group (defined in the specification text, but the excerpt you provided does not reproduce the drawn bicyclic options).
This layered approach makes the claims broad in chemical design space while still enforcing key “gating” features (ring Q pattern plus the 3,4 heterocycle bond condition plus the A/ring Q bicyclic relationship).
Independent claim 1 (composition, formula (1) scaffold)
Claim 1 is the broadest composition claim in your excerpt:
- A pharmaceutical composition comprising:
- the heterocyclic compound of formula (1) (or a salt) as active ingredient
- plus a pharmaceutically acceptable carrier
- With built-in structural conditions:
- ring Q pattern restricted to the —NH—CH2— / —N═CH— / —CH2—NH— / —CH═N— set
- 3-position to 4-position bond in the heterocyclic skeleton is single or double
- ring Q has at least one substituent chosen from the listed set
- R2 is H or lower alkyl
- A is —O-A1- (where A1 is an alkylene optionally substituted with hydroxy or can be lower alkenylene) or lower alkylene
- If A is lower alkylene, ring Q must be bicyclic
Net effect: Claim 1 covers compositions of a potentially large number of analogs as long as they satisfy these gating structural definitions.
Independent claims 2 and 3 (composition claims to listed compounds)
Claim 2 recites a composition where the active ingredient is selected from six named heterocycles:
- 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one
- 7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-1H-quinolin-2-one
- 7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3,4-dihydro-1H-quinolin-2-one
- 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one
- 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1-methyl-3,4-dihydro-1H-quinolin-2-one
- 6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3,4-dihydro-1H-quinolin-2-one
Claim 3 is similar but swaps the core to isoquinolinone/“isoquinoline-1-one” variants:
- 7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3,4-dihydro-2H-isoquinolin-1-one
- 7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-3,4-dihydro-2H-isoquinolin-1-one
- 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-2-methyl-3,4-dihydro-2H-isoquinolin-1-one
- 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-3,4-dihydro-2H-isoquinoline-1-one
- 7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2H-isoquinolin-1-one
- 7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-2H-isoquinolin-1-one
Net effect: Claims 2 and 3 are “anchor point” coverage to specific members of the broader structural class, improving enforceability against known embodiments and likely corresponding examples in the spec.
Independent claim 4 (method of treating CNS depression)
Claim 4 claims a method for treating a CNS disorder selected from:
- depression
- endogenous depression
- major depression
- melancholy
- refractory depression
The method is:
- administering the formula (1) heterocyclic compound (or salt) to a human or animal
and includes the same formula structural conditions as claim 1 (ring Q pattern, 3-4 bond single/double, ring Q substituent list, R2, A, and the A/lower-alkylene forcing bicyclic Q condition).
Net effect: It ties the claimed chemical class to a therapeutic indication for psychiatric disorders, which is a common friction point in generic and follow-on development because the first party’s freedom-to-operate analysis must consider both composition and use coverage.
Dependent claims 5 and 6 (method tied to listed compounds)
- Claim 5: method (claim 4) where the active ingredient is selected from the same six quinolinone compounds as in claim 2.
- Claim 6: method (claim 4) where the active ingredient is selected from the six isoquinolinone compounds as in claim 3.
Net effect: These dependent claims provide additional enforceability against specific marketed or lead-candidate members of the family.
Where are the boundary lines that could narrow infringement?
Based on the claim text you provided, infringement is gated by these structural and conditional limitations:
1) Ring Q must match the specified bond/atom patterns
Ring Q is restricted to one of the listed connectivity motifs (the —NH—CH2— / —N═CH— / —CH2—NH— / —CH═N— group set). That prevents design-arounds that use different ring-atom connections for the analogous pharmacophore.
2) The heterocycle’s 3,4 bond must be single or double
This is not just a “generic double bond allowed”; it is tied to the “3-position and 4-position of the heterocyclic skeleton containing Z and Y.”
3) A versus ring Q bicyclic condition is a hard trigger
- A can be —O-A1- (with A1 being an alkylene optionally hydroxy-substituted or lower alkenylene), or it can be lower alkylene.
- If A is lower alkylene, then ring Q must be bicyclic.
This can be used as an engineering target:
- If a candidate uses a lower alkylene A linker, it must also meet the bicyclic Q requirement.
- If A uses —O-A1-, the bicyclic condition does not apply (as stated).
4) The “at least one substituent” language on ring Q
Claim 1 requires ring Q “may have at least one substituent selected from” the provided substituent list. Interpreting “may have at least one” as a positive requirement in the excerpt still means ring Q cannot omit substitution entirely if the claim construction treats the phrase as limiting. Practically, design-arounds often ensure at least one substituent exists, but for risk controls, the phrase should be treated as potentially limiting.
5) R2 is limited
R2 is H or lower alkyl.
How broad are claims 1-4 relative to claims 2-3 and the exemplified set?
Claims 2 and 3 are strict lists of 12 concrete structures (6 quinolinone and 6 isoquinolinone). They are narrow relative to claim 1 but have the practical advantage of being easy to map during FTO.
Claims 1 and 4 are broader because they cover analogs that preserve the ring Q constraint, the 3,4 bond condition, and the A/R2/substituent rules. If the exemplified set represents the “core truth” of the scaffold, claim 1 should reach beyond those exact names into additional substitutions that still meet the gating constraints.
Practical read-through:
- If a candidate molecule is structurally very close to the listed exemplars, it is likely captured by either claim 2 or 3 (composition) and claim 5 or 6 (use).
- If it is modified (for example, a different heterocyclic saturation state, methyl placement, or linker length) while staying within the formula gates, it is more likely to fall under claim 1/4 rather than the named lists.
What does this say about the patent landscape around US 8,349,840?
Positioning within a typical CNS small-molecule patent stack
A patent with:
- a general Markush-style structural formula claim for composition (claim 1)
- plus independent method of use for CNS depression (claim 4)
- plus multiple dependent compositions and methods naming specific embodiments (claims 2, 3, 5, 6)
often sits as a core scaffold patent in a family where follow-on patents typically include one or more of:
- salt forms
- specific stereochemistry or polymorphs
- additional therapeutic indications
- formulation and delivery systems
Without the bibliographic family data or citation network for US 8,349,840 from your input, the landscape can only be assessed at a structural level: US 8,349,840 is best treated as a dual-risk patent (composition + use) that is likely to complicate both generic entry and repurposing around the same chemical class.
Landscape risk drivers for competitors
Competitors should treat this patent as creating three main friction points:
- Chemical proximity risk
- If a compound falls inside formula (1) with the ring Q and A constraints, claim 1 and claim 4 risk increases even if the candidate is not one of the named exemplars.
- Named-entity risk
- If a compound matches one of the listed quinolinone or isoquinolinone structures, the claims 2/3 (composition) and 5/6 (method) are directly implicated.
- Therapeutic-position risk
- If a compound is used or labeled for the claimed depression set (depression, major depression, endogenous depression, melancholy, refractory depression), method claim exposure rises.
What is likely outside the patent’s “direct net”?
Based strictly on claim language, likely outside include:
- molecules that change ring Q connectivity outside the listed motifs
- molecules that use R2 not equal to H or a lower alkyl
- molecules that violate the A/lower-alkylene/bicyclic-Q relationship
- uses not within the listed CNS depression set, if the method claim is construed narrowly to those listed disorders (the claim states “selected from” these terms)
Claim-to-structure mapping checklist (fast screening)
For any candidate compound under evaluation against US 8,349,840, the screening logic derived from the claims is:
- Does it have the heterocyclic skeleton with Z and Y and a 3,4 bond that is single or double?
- Is ring Q defined with one of the allowed connectivity motifs (—NH—CH2—, —N═CH—, —CH2—NH—, —CH═N—)?
- Does ring Q carry at least one substituent from the extensive allowed list?
- Is R2 H or lower alkyl?
- Is A either —O-A1- (A1 alkylene possibly hydroxy-substituted or lower alkenylene) OR lower alkylene?
- If A is lower alkylene, is ring Q bicyclic as required?
- If the molecule matches one of the 12 named structures, is it in the quinolinone or isoquinolinone set (claims 2/3)?
- If used for depression-related disorders in the claim list, method claims (claims 4-6) become relevant.
Key Takeaways
- US 8,349,840 has both composition and CNS depression method coverage, built from a broad formula (claim 1 for compositions; claim 4 for use) and reinforced by named-member coverage for 12 specific compounds (claims 2, 3, 5, 6).
- The claim scope is controlled by three gating elements: ring Q connectivity motif, the heterocycle 3,4 bond single/double constraint, and the A versus ring Q bicyclic condition.
- For landscape positioning, this patent behaves like a core scaffold/use patent: competitors must design around structural gating limits and also consider indication-specific method exposure for depression-related disorders.
FAQs
1. Does the patent cover salts?
Yes. All relevant claim sets state “or a salt thereof” for the active ingredient.
2. What psychiatric indications are covered by the method claim?
Depression, endogenous depression, major depression, melancholy, and refractory depression.
3. Are exact structures listed in claims 2 and 3, or is it purely formula coverage?
Both. Claims 2 and 3 list specific quinolinone and isoquinolinone structures, while claim 1 covers the broader formula-defined scaffold.
4. What is the most important design-around constraint besides the general scaffold?
The conditional relationship where if A is lower alkylene, ring Q must be bicyclic, plus the restricted ring Q connectivity motifs.
5. Is method protection dependent on selecting one of the listed compounds?
No. Claim 4 covers the formula (1) class broadly; claims 5 and 6 add protection specifically for the named quinolinone and isoquinolinone compounds.
References
[1] US Patent 8,349,840. (Claims text provided in the prompt: claims 1-6).
